Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CELU vs FBRX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FBRX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–0 Matrix Metrics)

FBRX Overall Winner 6-Pillar Tally: CELU 2 – 3 FBRX (1 Tie) Matrix Metrics: CELU 0 – 8 FBRX

As of Nov 20, 2026, Forte Biosciences, Inc. (FBRX) is the stronger overall head-to-head candidate over Celularity Inc. (CELU) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). CELU carries a Unified Composite Score of 42.9/100 (HOLD) at $0.46 (N/M Forward P/E, -254.0% operating margin), whereas FBRX carries 52.7/100 (HOLD) at $76.99 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: CELU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9); meanwhile FBRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CELU vs FBRX
CELU NASDAQ
Celularity Inc. Class A Common Stock
Pharmaceutical Preparations
$0.46
-1.05% 1D
Market Cap $15.2M
TTM Revenue $19M
Forward P/E N/M
Beta / 30D Vol 2.01β · 135% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 25.0 Fund 48.0 Flow 67.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.3%), weak momentum, RSI 27
RSI-14: 26.9 · SMA20: $0.71 · SMA50: $1.08
FBRX NASDAQ Head-to-Head Winner
Forte Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$76.99
+0.03% 1D
Market Cap $1.6B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.09β · 3% Vol
Unified Composite Score
52.7 / 100 HOLD
Tech 49.0 Fund 51.0 Flow 62.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (78.3% over 20 days), RSI 85
RSI-14: 84.7 · SMA20: $76.83 · SMA50: $52.74

6-Pillar Scorecard Institutional Category Breakdown (CELU 2 – 3 FBRX)

Columns: Metric · CELU · FBRX
1. Valuation Multiples CELU
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 2.7x N/M
2. Growth & Scale FBRX
Revenue Growth (YoY) -5.3% +0.0%
Earnings Growth (YoY) -61.3% +0.0%
TTM Revenue (USD) $19M N/A
Market Cap $15.2M $1.6B
3. Profitability & Quality FBRX
Gross Margin 19.2% N/A
Operating Margin -254.0% 0.0%
Net Profit Margin -245.7% 0.0%
Return on Equity (ROE) -6367.2% -62.3%
4. Balance Sheet & Cash Flow CELU
Cash Generation (TTM) -$8.9M -$72M
Cash Flow Margin -47.8% N/A
Net Cash / Leverage $35M Net Debt $7.52 Book/Sh · -62.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning FBRX
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 116.6% (50th %ile) 11.1% (3rd %ile)
Put/Call OI Skew 3.60x (Put-Skewed) 0.77x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CELU (0) vs FBRX (8)
Institutional Metric CELU FBRX Criterion Row Edge
Market Capitalization
Scale
$15.2M $1.6B Larger Scale FBRX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-5.3% +0.0% Higher Growth FBRX
Operating Margin (TTM)
Profitability
-254.0% 0.0% Higher Margin FBRX
Net Profit Margin
Profitability
-245.7% 0.0% Higher Margin FBRX
Return on Equity (ROE)
Capital Efficiency
-6367.2% -62.3% Higher ROE FBRX
52-Week Range Position
Momentum
2% ($0–$3) 100% ($10–$77) Stronger Trend FBRX
Beta / 30D Volatility
Risk Regime
2.01β · 135% Vol 1.09β · 3% Vol Lower Realized Risk FBRX
Unified Institutional Score
Composite Signal
42.9 / 100 (HOLD) 52.7 / 100 (HOLD) Higher Composite FBRX
Trailing 12M Revenue (USD)
Operating Scale
$19M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
19.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.7x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$8.9M ($35M Net Debt) -$72M ($7.52 Book/Sh · -62.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CELU +15.39 pp
CELU: +15.83% · FBRX: +0.44%
3M Horizon FBRX +262.38 pp
CELU: -3.79% · FBRX: +258.59%
6M Horizon FBRX +200.28 pp
CELU: -29.57% · FBRX: +170.71%
1Y Horizon FBRX +359.4 pp
CELU: -47.91% · FBRX: +311.49%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CELU Revenue FBRX Revenue CELU Op. Margin FBRX Op. Margin Margin Leader
FY2018 N/A $20M N/A -254.2% FBRX
FY2019 N/A $0M N/A -11288.9% FBRX
FY2020 $10M N/A -1064.0% N/A CELU
FY2021 $20M N/A -511.2% N/A CELU
FY2022 $20M N/A -142.4% N/A CELU
FY2023 $20M N/A -844.4% N/A CELU
FY2024 $50M N/A -70.7% N/A CELU
FY2025 $30M N/A -230.9% N/A CELU

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CELU BREAKDOWN
60d in phase · OBV NEUTRAL
Current IV 116.6%
IV Percentile 50th %ile
Put/Call OI Skew 3.60x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CELU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FBRX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 11.1%
IV Percentile 3rd %ile
Put/Call OI Skew 0.77x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact FBRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CELU Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.2M market capitalization and -254.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FBRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.6B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CELU vs FBRX Key Questions & Quantitative Answers

As of Nov 20, 2026, Forte Biosciences, Inc. (FBRX) is the stronger overall head-to-head candidate over Celularity Inc. (CELU) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). CELU carries a Unified Composite Score of 42.9/100 (HOLD) at $0.46 (N/M Forward P/E, -254.0% operating margin), whereas FBRX carries 52.7/100 (HOLD) at $76.99 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: CELU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9); meanwhile FBRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FBRX leads the Growth & Scale pillar: CELU posts -5.3% YoY revenue growth and -61.3% YoY earnings growth on $19M TTM revenue (19.2% gross margin, -254.0% operating margin), compared with FBRX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CELU cumulative revenue shifted +200.0% while FBRX shifted N/A. In operating R&D and SG&A reinvestment, CELU deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FBRX.

CELU screens cheaper on headline valuation multiples. CELU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.7x EV/Revenue (-47.8% FCF margin), whereas FBRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CELU (-6367.2% ROE) versus FBRX (-62.3% ROE) capital efficiency.

In options market volatility and institutional positioning, CELU carries 116.6% implied volatility (50th %ile, Balanced (25th–60th %ile)), a 3.60x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.01β · 135% Vol realized risk). By comparison, FBRX carries 11.1% implied volatility (3rd %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.09β · 3% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.